{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:07:07Z","timestamp":1789034827865,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":176,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009667","name":"School of Medicine, Kyorin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009667","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.101043","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:31:57Z","timestamp":1783009917000},"page":"101043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serological Remission Defined by Anti-Integrin \u03b1v\u03b26 Antibody Predicts Long-Term Clinical Remission of Ulcerative Colitis"],"prefix":"10.1016","volume":"5","author":[{"given":"Noriaki","family":"Oguri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Kamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Fujima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Ogihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Morikubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2026.101043_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101043_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2026.101043_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.gastha.2026.101043_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/jcm11020400","article-title":"The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis","volume":"11","author":"Ka\u0142u\u017cna","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastha.2026.101043_bib5","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101043_bib6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101043_bib7","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101043_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review","volume":"14","author":"Colombel","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2026.101043_bib9","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2026.101043_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","article-title":"Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis","volume":"11","author":"Shinzaki","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2026.101043_bib11","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/MIB.0000000000000062","article-title":"Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis","volume":"20","author":"Arai","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2026.101043_bib12","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2024.08.003","article-title":"Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments","volume":"45","author":"Wangchuk","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.gastha.2026.101043_bib13","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1053\/j.gastro.2021.02.019","article-title":"Identification of an anti-integrin \u03b1v\u03b26 autoantibody in patients with ulcerative colitis","volume":"160","author":"Kuwada","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101043_bib14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1053\/j.gastro.2022.06.026","article-title":"Anti-integrin \u03b1v\u03b26 antibody as a diagnostic marker for pediatric patients with ulcerative colitis","volume":"163","author":"Muramoto","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101043_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00535-024-02176-x","article-title":"Anti-integrin \u03b1v\u03b26 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study","volume":"60","author":"Okabe","year":"2025","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101043_bib16","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.3390\/jcm11071881","article-title":"Measurement of serum IgG anti-integrin \u03b1v\u03b26 autoantibodies is a promising tool in the diagnosis of ulcerative colitis","volume":"11","author":"Rydell","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastha.2026.101043_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies are a novel biomarker that antedate ulcerative colitis","volume":"164","author":"Livanos","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101043_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.dld.2023.06.024","article-title":"Diagnostic value of anti-integrin \u03b1v\u03b26 antibodies in ulcerative colitis","volume":"56","author":"Marafini","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastha.2026.101043_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf062","article-title":"Anti-integrin \u03b1v\u03b26 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: a cross-sectional and longitudinal study defining a specific disease phenotype","volume":"19","author":"Pertsinidou","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"Pt 6","key":"10.1016\/j.gastha.2026.101043_bib20","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1242\/jcs.108.6.2241","article-title":"Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling","volume":"108","author":"Breuss","year":"1995","journal-title":"J Cell Sci"},{"key":"10.1016\/j.gastha.2026.101043_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/cbin.10258","article-title":"Alphavbeta6 is required in maintaining the intestinal epithelial barrier function","volume":"38","author":"Yu","year":"2014","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.gastha.2026.101043_bib22","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41591-022-01680-y","article-title":"Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity","volume":"28","author":"Uzzan","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.gastha.2026.101043_bib23","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJMc2508023","article-title":"CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis","volume":"393","author":"M\u00fcller","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2026.101043_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1641329","article-title":"Antibodies against integrin \u03b1v\u03b26 have high diagnostic accuracy for ulcerative colitis","volume":"16","author":"Bez","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.gastha.2026.101043_bib25","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/ibd\/izy300","article-title":"Efficacy of therapeutic intervention for patients with an ulcerative colitis Mayo endoscopic score of 1","volume":"25","author":"Fukuda","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2026.101043_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/ecco-jcc\/jjv180","article-title":"Mucosal healing in ulcerative colitis\u2013when zero is better","volume":"10","author":"Boal Carvalho","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2026.101043_bib27","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1097\/MIB.0000000000001275","article-title":"Impact of histological and endoscopic remissions on clinical recurrence and recurrence-free time in ulcerative colitis","volume":"23","author":"Ponte","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2026.101043_bib28","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2020.06.043","article-title":"Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis","volume":"159","author":"Yoon","year":"2020","journal-title":"Gastroenterology"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326001640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326001640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:14:11Z","timestamp":1789031651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572326001640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572326001640"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.101043","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological Remission Defined by Anti-Integrin \u03b1v\u03b26 Antibody Predicts Long-Term Clinical Remission of Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.101043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}],"article-number":"101043"}}